How Does WES Contribute to Cancer Biomarker Discovery?
WES is instrumental in discovering new biomarkers for cancer diagnosis, prognosis, and treatment response. By sequencing the exomes of large cohorts of cancer patients, researchers can identify common mutations and correlate them with clinical outcomes. For instance, mutations in the BRCA1 and BRCA2 genes are well-known biomarkers for increased risk of breast and ovarian cancers.
